Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cidara Therapeutics

21.50
-0.1900-0.88%
Post-market: 21.500.00000.00%19:20 EDT
Volume:27.29K
Turnover:590.25K
Market Cap:269.75M
PE:-0.80
High:22.00
Open:21.55
Low:21.22
Close:21.69
Loading ...

Cidara Therapeutics Names Nicole Davarpanah as Chief Medical Officer

MT Newswires Live
·
01 May

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to Svp, Clinical Development

THOMSON REUTERS
·
01 May

Press Release: Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

Dow Jones
·
01 May

Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice

Zacks
·
01 May

Cidara Therapeutics Price Target Maintained With a $46.00/Share by JMP Securities

Dow Jones
·
30 Apr

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

GlobeNewswire
·
24 Apr

Cidara Therapeutics Price Target Maintained With a $35.00/Share by Needham

Dow Jones
·
10 Apr

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
02 Apr

Elicio Therapeutics Names Preetam Shah CFO

MT Newswires Live
·
24 Mar

Elicio Therapeutics Hires CFO From Cidara Therapeutics

Dow Jones
·
24 Mar

Positive Buy Rating for Cidara Therapeutics Driven by Promising CD388 Development and Safety Profile

TIPRANKS
·
19 Mar

Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology

GlobeNewswire
·
17 Mar

Cidara Therapeutics initiated with an Outperform at Citizens JMP

TIPRANKS
·
12 Mar

Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention

TIPRANKS
·
12 Mar

Cidara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
10 Mar

Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright

TIPRANKS
·
10 Mar

Cidara Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $35 From $24

THOMSON REUTERS
·
10 Mar

Cidara Therapeutics Faces Financial Risks Amid Delayed Annual Report Filing

TIPRANKS
·
08 Mar

Cidara Therapeutics Advances with Strong Financial Backing

TIPRANKS
·
08 Mar

Buy Rating for Cidara Therapeutics Driven by Phase 2b Trial Progress and Strong Financial Position

TIPRANKS
·
07 Mar